Lipo-C
$154.00Lipo-C is a compounded MIC (methionine, inositol, choline) blend with B-vitamins studied for hepatic lipid metabolism and methyl-group transfer. See composition and specifications.
Showing all 9 results

Lipo-C is a compounded MIC (methionine, inositol, choline) blend with B-vitamins studied for hepatic lipid metabolism and methyl-group transfer. See composition and specifications.

PT-141 (bremelanotide) is a 7-amino-acid MC4R-selective melanocortin agonist studied for central sexual-behavior signaling. See PT-141 vs Melanotan 2 and specifications.

Semaglutide is the GLP-1 research peptide. See mechanism, how it compares to tirzepatide, and full specifications. 5mg and 20mg vials.

SLU-PP-332 is a selective pan-ERR (estrogen-related receptor) agonist studied for mitochondrial biogenesis, oxidative metabolism, and exercise-mimetic endpoints. See mechanism and specifications.

Tirzepatide is the dual GLP-1/GIP research peptide. See mechanism, how it compares to semaglutide and retatrutide, and full specifications. 10mg and 60mg vials.

WWP-3X (Reta) – research-grade lyophilized triple-agonist peptide (GLP-1, GIP, glucagon receptors). Specifications, purity, aliases, and storage information for laboratory research use only.

WWP-4X (Survo) (BI 456906) is a once-weekly glucagon / GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. See mechanism, comparisons, and specifications. 10mg.

WWP-5X (Cagri) is a long-acting amylin analog developed by Novo Nordisk, studied alongside and paired with semaglutide (CagriSema). See mechanism, comparisons, and specifications. 5mg and 10mg.

WWP-6X (Cagri/Sema) is the co-formulated amylin + GLP-1 combination (cagrilintide / semaglutide) developed by Novo Nordisk. See mechanism, REDEFINE trial context, and specifications. 5/5mg blend.
